The allowed claims cover MyMD’s Supera-CBD(TM) compound as a new molecular entity and pharmaceutical formulations containing the compound.
The allowed claims cover MyMD’s Supera-CBD(TM) compound as a new molecular entity and pharmaceutical formulations containing the compound.